Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Transl Res. 2021 Jan 2;233:92–103. doi: 10.1016/j.trsl.2020.12.009

Table 1.

Associations of seven validated significant SNPs with overall survival in both discovery and validation datasets from two previously published NSCLC GWAS datasets

SNP Allelea Gene PLCO (n=1185) HLCS (n=984) Combined-analysis
FDRa BFDPa MAF HR (95% CI)b Pb MAF HR (95% CI)c Pc Phetd I2 HR (95% CI)e Pe
rs2237078f G>C HBEGF 0.555 0.735 0.22 0.85 (0.74–0.96) 0.010 0.21 0.86 (0.75–0.99) 0.033 0.904 0 0.85 (0.78–0.94) 0.0010
rs4150230f G>A HBEGF 0.547 0.747 0.22 0.84 (0.74–0.96) 0.009 0.21 0.84 (0.73–0.96) 0.013 1.000 0 0.84 (0.76–0.92) 0.0003
rs4150232f G>A HBEGF 0.547 0.747 0.22 0.84 (0.74–0.96) 0.009 0.21 0.83 (0.72–0.96) 0.012 0.904 0 0.84 (0.76–0.92) 0.0002
rs4150234f G>A HBEGF 0.547 0.747 0.22 0.84 (0.74–0.96) 0.008 0.21 0.84 (0.73–0.96) 0.011 1.000 0 0.84 (0.76–0.92) 0.0003
rs4150236f G>A HBEGF 0.546 0.747 0.22 0.84 (0.74–0.96) 0.008 0.21 0.84 (0.73–0.96) 0.012 1.000 0 0.84 (0.76–0.92) 0.0003
rs13385f G>A HBEGF 0.556 0.735 0.22 0.85 (0.75–0.96) 0.011 0.21 0.86 (0.75–0.99) 0.030 0.902 0 0.85 (0.78–0.94) 0.0007
rs116454384 C>T ITPR3 0.556 0.747 0.17 0.84 (0.74–0.96) 0.012 0.19 0.87 (0.75–1.00) 0.049 0.723 0 0.85 (0.78–0.94) 0.0012

Abbreviations: SNP, single nucleotide polymorphism; NSCLC, non-small cell lung cancer; GWAS, genome-wide association study; PLCO, Prostate, Lung, Colorectal and Ovarian cancer screening trial; HLCS: Harvard Lung Cancer Susceptibility; MAF, minor allele frequency; HR, hazards ratio; CI, confidence interval; FDR: false discovery rate; BFDP: Bayesian false discovery probability

a

FDR and BFDP were available in the PLCO dataset because the HLCS study provided only the summary data

b

Obtained from an additive genetic model with adjustment for age, sex, stage, histology, smoking status, chemotherapy, radiotherapy, surgery, PC1, PC2, PC3, and PC4;

c

Obtained from an additive genetic model with adjustment for age, sex, stage, histology, smoking status, chemotherapy, radiotherapy, surgery, PC1, PC2, and PC3;

d

Phet: P value for heterogeneity by Cochrane’s Q test;

e

Meta-analysis in the fixed-effects model.

f

SNPs rs2237078, rs4150230, rs4150232, rs4150234, rs13385 are high LD with rs4150236.